London-based BenevolentAI, an AI company with pharmaceutical discovery and clinical development capabilities, has raised $115 million at a pre-money valuation of $2 billion, in one of the largest funding rounds in the AI pharmaceutical sector.
The majority of investors are from the United States. The balance of raised funds came from existing investors, including Woodford Investment Management, said the company in a statement. Credit Suisse acted as the placement agent for the company. Additional details of the financing was not disclosed.
BenevolentAI has raised more than $200 million in funding since its inception in 2013. The company was founded by Ken Mulvany.
Read a blog post by Mr. Mulvany on the funding here.
[Image courtesy: BenevolentAI]